Were N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Registrars:
Capita Registrars
Key Personnel
CEO:
Nigel Theobald
Executive Director:
Luke Cairns, David Templeton
Non-Executive Chairman:
Chris Britten
Independent Non-Executive Director:
Alastair Smith
Vice Chairman and CEO:
Michael Palfreyman
Contact Details
Address:
6th Floor, 60 Gracechurch Street, London, United Kingdom